Sunovion Pharmaceuticals Inc.’s Investigational Ciclesonide HFA Nasal Aerosol Effective in Treatment of Seasonal Allergic Rhinitis Symptoms

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced that data from a large scale, 671-patient, Phase III clinical study of ciclesonide nasal aerosol in a hydrofluoroalkane (HFA) formulation were presented in three separate scientific posters at the 2011 annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Francisco, California. The data show statistically significant improvements in reflective total ocular symptom score (rTOSS) in patients treated once daily with 74 µg of ciclesonide nasal aerosol as well as statistically significant improvements in nasal symptoms of seasonal allergic rhinitis (SAR) in patients treated once daily with both 74 µg and 148 µg of ciclesonide nasal aerosol. The overall incidence of adverse events (including epistaxis) was low and comparable to placebo. Furthermore, the data also demonstrated statistically significant improvements with 74 µg of ciclesonide nasal aerosol in the overall rhinoconjunctivitis quality of life questionnaire (RQLQ) vs. placebo with a difference of 0.64.